
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26075508</article-id><article-id pub-id-type="pmc">4488726</article-id><article-id pub-id-type="doi">10.3390/v7062759</article-id><article-id pub-id-type="publisher-id">viruses-07-02759</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>IFITMs from Mycobacteria Confer Resistance to Influenza Virus When Expressed in Human Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Melvin</surname><given-names>William J.</given-names></name><xref ref-type="author-notes" rid="fn1-viruses-07-02759">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>McMichael</surname><given-names>Temet M.</given-names></name><xref ref-type="author-notes" rid="fn1-viruses-07-02759">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Chesarino</surname><given-names>Nicholas M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hach</surname><given-names>Jocelyn C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yount</surname><given-names>Jacob S.</given-names></name><xref rid="c1-viruses-07-02759" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Freed</surname><given-names>Eric O.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-07-02759">Department of Microbial Infection and Immunity, Center for Microbial Interface Biology, the Ohio State University, Columbus, OH 43210, USA; E-Mails: <email>wjamesmelvin@gmail.com</email> (W.J.M.); <email>temet.mcmichael@osumc.edu</email> (T.M.M.); <email>chesarino.1@osu.edu</email> (N.M.C.); <email>jocelyn.hach@gmail.com</email> (J.C.H.)</aff><author-notes><fn id="fn1-viruses-07-02759"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn><corresp id="c1-viruses-07-02759"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>yount.37@osu.edu</email>; Tel.: +1-614-688-1639.</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2015</year></pub-date><volume>7</volume><issue>6</issue><fpage>3035</fpage><lpage>3052</lpage><history><date date-type="received"><day>09</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2015</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Interferon induced transmembrane proteins (IFITMs) found in vertebrates restrict infections by specific viruses. IFITM3 is known to be essential for restriction of influenza virus infections in both mice and humans. Vertebrate IFITMs are hypothesized to have derived from a horizontal gene transfer from bacteria to a primitive unicellular eukaryote. Since bacterial IFITMs share minimal amino acid identity with human IFITM3, we hypothesized that examination of bacterial IFITMs in human cells would provide insight into the essential characteristics necessary for antiviral activity of IFITMs. We examined IFITMs from <italic>Mycobacterium avium</italic> and <italic>Mycobacterium abscessus</italic> for potential antiviral activity. Both of these IFITMs conferred a moderate level of resistance to influenza virus in human cells, identifying them as functional homologues of IFITM3. Analysis of sequence elements shared by bacterial IFITMs and IFITM3 identified two hydrophobic domains, putative <italic>S</italic>-palmitoylation sites, and conserved phenylalanine residues associated with IFITM3 interactions, which are all necessary for IFITM3 antiviral activity. We observed that, like IFITM3, bacterial IFITMs were <italic>S</italic>-palmitoylated, albeit to a lesser degree. We also demonstrated the ability of a bacterial IFITM to co-immunoprecipitate with IFITM3 suggesting formation of a complex, and also visualized strong co-localization of bacterial IFITMs with IFITM3. However, the mycobacterial IFITMs lack the endocytic-targeting motif conserved in vertebrate IFITM3. As such, these bacterial proteins, when expressed alone, had diminished colocalization with cathepsin B-positive endolysosomal compartments that are the primary site of IFITM3-dependent influenza virus restriction. Though the precise evolutionary origin of vertebrate IFITMs is not known, our results support a model whereby transfer of a bacterial IFITM gene to eukaryotic cells may have provided a selective advantage against viral infection that was refined through the course of vertebrate evolution to include more robust signals for <italic>S</italic>-palmitoylation and localization to sites of endocytic virus trafficking.</p></abstract><kwd-group><kwd>interferon induced transmembrane protein</kwd><kwd>IFITM3</kwd><kwd>influenza virus</kwd><kwd>virus restriction</kwd><kwd>palmitoylation</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>Interferon-induced transmembrane proteins (IFITMs) encoded by a variety of vertebrates, including pigs, chickens, bats, fish, mice, and humans, have been shown to restrict cellular infection by specific viruses [<xref rid="B1-viruses-07-02759" ref-type="bibr">1</xref>,<xref rid="B2-viruses-07-02759" ref-type="bibr">2</xref>,<xref rid="B3-viruses-07-02759" ref-type="bibr">3</xref>,<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B5-viruses-07-02759" ref-type="bibr">5</xref>,<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>]. IFITMs inhibit viruses that fuse within cellular endosomes [<xref rid="B7-viruses-07-02759" ref-type="bibr">7</xref>,<xref rid="B8-viruses-07-02759" ref-type="bibr">8</xref>] by preventing the formation of the viral fusion pore [<xref rid="B9-viruses-07-02759" ref-type="bibr">9</xref>,<xref rid="B10-viruses-07-02759" ref-type="bibr">10</xref>]. As a result of the block to viral entry through endosomes, virus is subsequently degraded in cathepsin-positive endolysosomes [<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>,<xref rid="B11-viruses-07-02759" ref-type="bibr">11</xref>]. However, the molecular mechanisms by which IFITMs exert their antiviral functions and the precise evolutionary history of vertebrate IFITMs remain unknown [<xref rid="B12-viruses-07-02759" ref-type="bibr">12</xref>,<xref rid="B13-viruses-07-02759" ref-type="bibr">13</xref>].</p><p>The essentiality of mouse IFITM3 in restricting influenza virus infection was demonstrated by showing that IFITM3 knockout mice succumb to sublethal doses of virus and exhibit higher lung titers and more severe lung pathology than wild type mice [<xref rid="B14-viruses-07-02759" ref-type="bibr">14</xref>,<xref rid="B15-viruses-07-02759" ref-type="bibr">15</xref>]. Similarly, a nucleotide polymorphism in the human IFITM3 gene that is thought to affect proper IFITM3 RNA splicing has been associated with increased severity of influenza virus-associated disease [<xref rid="B14-viruses-07-02759" ref-type="bibr">14</xref>,<xref rid="B16-viruses-07-02759" ref-type="bibr">16</xref>,<xref rid="B17-viruses-07-02759" ref-type="bibr">17</xref>,<xref rid="B18-viruses-07-02759" ref-type="bibr">18</xref>]. Thus, IFITM3 is necessary for the innate immune restriction of influenza virus in mice and humans, and further understanding its biochemical properties may inspire new strategies for preventing or treating influenza and other IFITM-sensitive virus infections.</p><p>An extensive evolutionary study of IFITMs posited that vertebrate IFITMs originated from a horizontal gene transfer from bacteria to a common ancestor of choanoflagellates and metazoans [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>]. Whether or not transfer of an IFITM gene provided an immediate antiviral selective advantage to eukaryotic cells is not known. Likewise, the function of IFITMs in bacteria has not been studied, though they have been annotated in numerous bacterial species including multiple mycobacterial strains [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>]. Here, we examined the effect on influenza virus infection when mycobacterial IFITMs were expressed in human cells. Despite having roughly 20% amino acid identity with human or mouse IFITM3, we found that two divergent mycobacterial IFITMs each provided measurable inhibition of influenza virus infection of human cells. Surprisingly, we found that several essential characteristics necessary for the antiviral activity of IFITM3 are conserved in mycobacterial IFITMs, and speculate that the functional homology between mycobacterial IFITMs and vertebrate IFITM3 may be utilized to better understand both the evolutionary path of human IFITM3 and the amino acid determinants that make IFITM3 such a potent antiviral restriction factor.</p></sec><sec><title>2. Materials and Methods</title><sec><title>2.1. Plasmids, Cloning, and Bioinformatics</title><p>Expression constructs in the pCMV-HA vector or pCMV-myc vectors (Clontech, Mountain View, CA, USA) encoding mouse and human HA-IFITM3, human myc-IFITM3, and mouse HA-IRGM1 have been previously described [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B21-viruses-07-02759" ref-type="bibr">21</xref>]. Untagged human IFITM3 was generated by removal of the HA tag from the pCMV-HA vector by site directed mutagenesis. mEmerald-Cathepsin B was a kind gift from Michael Davidson via Addgene (plasmid #54024). Human codon-optimized DNA sequences were generated from the amino acid sequences for MAV IFITM (UniProt A0QLS9) and MAB IFITM (UniProt B1MKV5). These sequences were purchased as synthetic Gene Strings from Life Technologies (Carlsbad, CA, USA). The complete sequences that were ordered including EcoRI and SalI restriction sites are shown below. These sequences were inserted into the pCMV-HA vector in frame with the HA tag via restriction sites. Phylogenetic tree analysis of the mycobacterial IFITMs, alignments, and calculations of percent amino acid identities were performed using Clustal Omega software (University College Dublin, Dublin, Ireland).</p><preformat>MAV IFITM
GAATTCCCATGACCCAACCACCTCCTCCCCCGCCACCACCAGGATATCCCCCACAACAGCCAGCCGCTCAGGCTCCTAATAACTATCTGGTGTGGTCTATCCTTGTCACTCTCTTCTGCTGCCTGCCGTTTGGCATTGTCGCTATCGTAAAGAGCTCTCAAGTGAACGGACTTTGGGCACAGGGTAGATATGCTGAGGCACAGGCCTCCGCAGACAGTGCCAAGAAATGGGTGATATGGAGCGCAGTTATAGGCGTCGTGGTGGGAATAATCTATGGAATCCTTATGGCCGTAGGCGCCCTCAACACAAATACAAACGCGGCCCTCGCCGCGATGTTTTAGTAAGTCGAC
        </preformat><preformat>MAB IFITM
GAATTCCCATGAGTGATGAAACCAAAAGCGACGAGCCTACAGGCGCTATCACCACACCGACCCCTCCTCCCCCACCGGCTCCTGCCTCTGTGACTGGCCCACCCAAACCCCCACCCACTAACGTGGGTTGGGCCGTCGCTAGCGTGATTTTTTTCTGGCCTCTGGCATTTAGCGCATTCACCAATGCACTGAATGTGACTCAGTTTTGGCTGACGGGGCAGTATGATCGGGCCCAGGAGTCTAGCGATCGGGCCAAGCTCCTGGGAAAGATTGCCCTCCTGACCGGGTTGGTACTGCTGTTCCTGTTCATCACCCTCCGCATTGCCTGCGCCATCTGGTGGCACTCACATGGTGGGGGATGGGGTCATCATGGCGGATGGCATAGGAGTTGGGACGACGGCGGGTGGGATGGCCCTGGCCCCATCGGGCCTATGGGTAGGCCGGGTCGCGACAACTAGTAAGTCGAC
</preformat></sec><sec><title>2.2. Cells, Transfections, Palmitoylation Assay, and Virus Infections</title><p>HEK293T cells were obtained from the ATCC and were grown in DMEM supplemented with 10% FBS (Sigma, St. Louis, MO, USA) in a humidified incubator with 5% CO<sub>2</sub> at 37 &#x000b0;C. For imaging experiments, cells were grown on sterilized glass coverslips in 12-well plates. For all other experiments, cells were grown in 12-well or 6-well plates. Cells were transfected overnight using LipoJet (SignaGen Laboratories, Gaithersburg, MD, USA) according to the manufacturer&#x02019;s instructions. For biochemical experiments, 2 ug/well of each plasmid was transfected into cells grown in 6-well plates. For infection experiments, 1 ug/well of each plasmid was transfected into cells grown in 12-well plates, with the exception of plasmid encoding HA-MAB IFITM for which 0.5 ug/well was transfected. For examination of palmitoylation, transfected cells were labeled with 50 uM alk-16 for 1 h as previously described in detail [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B22-viruses-07-02759" ref-type="bibr">22</xref>,<xref rid="B23-viruses-07-02759" ref-type="bibr">23</xref>]. Immunoprecipitiated proteins were then reacted with azido-rhodamine via click chemistry, subjected to SDS-PAGE, and visualized by fluorescent gel scanning [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B22-viruses-07-02759" ref-type="bibr">22</xref>,<xref rid="B23-viruses-07-02759" ref-type="bibr">23</xref>]. Influenza viruses strains A/Puerto Rico/8/34 (H1N1, known as PR8) and the PR8 H3N2 reassortant virus strain known as X-31 were grown in 10-day embryonated chicken eggs for 48 h at 37 &#x000b0;C as described previously [<xref rid="B24-viruses-07-02759" ref-type="bibr">24</xref>]. Sendai virus strain Cantell was grown in 10-day embryonated eggs for 40 h at 37 &#x000b0;C as described previously [<xref rid="B25-viruses-07-02759" ref-type="bibr">25</xref>]. Cells were infected by replacing cellular media with 400 uL warm media containing virus. Infections were allowed to proceed for 6 h at 37 &#x000b0;C before collection of cells and analysis by flow cytometry.</p></sec><sec><title>2.3. Western Blotting, Immunoprecipitations, Immunofluorescence, and Flow Cytometry</title><p>For palmitoylation experiments, cells were lysed with 1% Brij Buffer (50 mM triethanolamine, 150 mM NaCl, 1% BrijO10 (Sigma), pH 7.4) containing EDTA-free protease inhibitor cocktail. For co-immunoprecipitation experiments, cells were lysed with 1% digitonin in PBS containing EDTA-free protease inhibitor cocktail. Immunoprecipitations were performed with either anti-HA or anti-myc EzView Affinity Gel (Sigma). For palmitoylation experiments, immunoprecipitations were washed 3 times with standard RIPA buffer (50 mM triethanolamine, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X100, 0.1% SDS, pH 7.4), and for co-immunoprecipitation experiments, the immunoprecipitations were washed 5 times with 0.1% digitonin in PBS. All detergents were purchased from Sigma. Western blotting was performed with anti-HA antibody (Covance, Dedham, MA, USA, HA.11, 1:1000) or anti-myc antibody (Developmental Studies Hybridoma Bank, Iowa City, IA, USA, 9E10, 1:1000). For immunofluorescence and flow cytometry, cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X100 in PBS for 10 min, and blocked with 2% FBS in PBS for 10 min. For immunofluorescence, cells were stained with the anti-HA or anti-myc antibodies described above that were directly labeled with Alexafluor 488 or 555 using 100 ug antibody kits from Life Technologies. Slides were mounted with Prolong Gold Antifade Reagent containing DAPI from Life Technologies and images were taken using an Olympus Fluoview FV10i confocal microscope. Quantification of Manders overlap coefficients was performed using the Just Another Colocalization Plugin (JACoP) for ImageJ software. For flow cytometry, cells were stained with anti-IFITM3 antibody (Cell Signaling, Boston, MA, USA) and anti-rabbit-Alexafluor-488 secondary antibody (Life Technologies), or with anti-HA antibody directly conjugated to Alexafluor-488 and anti-influenza NP antibody (Abcam, Cambridge, UK, ab20343) directly conjugated to Alexafluor-647 as previously described [<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>], or anti-Sendai virus antibody (MBL International Corporation, Woburn, MA, USA, PD029) with anti-rabbit-Alexafluor-647 secondary antibody (Life Technologies). Cells were analyzed using a BD Biosciences FACSCanto II flow cytometer (Franklin Lakes, NJ, USA) and Flowjo software (Ashland, OR, USA).</p></sec></sec><sec><title>3. Results</title><sec><title>3.1. Commonalities and Differences between IFITM3 and Mycobacterial IFITMs</title><p>Evolutionary studies of the IFITM gene family have identified numerous IFITM genes in different vertebrates [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>,<xref rid="B26-viruses-07-02759" ref-type="bibr">26</xref>,<xref rid="B27-viruses-07-02759" ref-type="bibr">27</xref>]. One study also identified more than 40 IFITM-related genes encoded by bacteria, and proposed that eukaryotic IFITMs derived from a horizontal gene transfer from bacteria to a single-celled ancestor of metazoans [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>]. We sought to examine whether or not a bacterial IFITM could confer resistance to virus infection of human cells. Among the bacterial IFITM sequences previously identified, nine belong to mycobacterial strains [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>]. A phylogenetic analysis of these nine amino acid sequences indicated that an IFITM from <italic>Mycobacterium abscessus</italic> (MAB) was significantly divergent from the majority of the remaining mycobacterial IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>A). For further analysis we chose the MAB IFITM and a <italic>Mycobacterium avium</italic> (MAV) IFITM as a representative of the more typical mycobacterial IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>A). ClustalO alignment of these two IFITMs along with human and mouse IFITM3 showed that the mycobacterial IFITMs share minimal sequence identity with human IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B,C, 14.1% identity for MAB IFITM and 18.8% for MAV IFITM). This is in contrast to the greater amino acid conservation shared between mouse and human IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B, 65.6%), which are known to be functional homologues. Since, like the mycobacterial IFITMs, human IFITM1 possesses a shortened N-terminus as compared to IFITM3, we also aligned the mycobacterial IFITMs with IFITM1 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). However, the amino acid conservation between IFITM1 and MAB IFITM was still only 19.2% and only 21.9% for MAV IFITM (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>D). One important difference we noted between MAB and MAV IFITMs and IFITM3 is the lack of a Yxx&#x003a6; motif in the N-terminus of the mycobacterial IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). We, and others, previously found that this tetrapeptide promotes the localization of IFITM3 to endosomes and lysosomes [<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B28-viruses-07-02759" ref-type="bibr">28</xref>,<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>]. Likewise, the mycobacterial IFITMs also lack the C-terminal di-basic endocytic motif that is alternatively utilized by human IFITM1 [<xref rid="B30-viruses-07-02759" ref-type="bibr">30</xref>] (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B).</p><p>Despite the major differences between the amino acid sequences of IFITM3 and mycobacterial IFITMs, a similar fundamental domain structure could be identified in each of these proteins. Two hydrophobic domains separated by approximately 30 amino acids are defining characteristics of IFITMs and were present in both MAV and MAB IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). Most vertebrate IFITMs also possess <italic>S</italic>-palmitoylated cysteines, including an <italic>S</italic>-palmitoylated di-cysteine motif, within the first hydrophobic domain [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B31-viruses-07-02759" ref-type="bibr">31</xref>,<xref rid="B32-viruses-07-02759" ref-type="bibr">32</xref>] (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). Interestingly, the di-cysteine motif is conserved within MAV IFITM, but not within MAB IFITM, though MAB IFITM possesses a cysteine in a location similar to a non-conserved <italic>S</italic>-palmitoylation site on murine IFITM1 [<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>] (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). Likewise, IFITM3 has been reported to homo-dimerize and hetero-dimerize with IFITM2, and this interaction is promoted by the presence of two redundant phenylalanines within the first hydrophobic domain [<xref rid="B34-viruses-07-02759" ref-type="bibr">34</xref>]. Interestingly, both MAB and MAV IFITMs have at least one phenylalanine within their first hydrophobic domains in positions similar to IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). Thus, despite the low amino acid identity between mycobacterial IFITMs and IFITM3, their domain architecture is conserved along with several specific residues that are particularly critical for IFITM3 antiviral activity.</p><fig id="viruses-07-02759-f001" position="float"><label>Figure 1</label><caption><p>IFITMs from mycobacteria are divergent from vertebrate IFITMs, but possess certain shared amino acid sequence elements. (<bold>A</bold>) A phylogenetic tree of mycobacterial IFITMs generated with Clustal Omega alignments. The mycobacterial species and corresponding UniProt accession number for each IFITM is indicated. IFITMs from MAB (<italic>M. abscessus</italic>) and MAV (<italic>M. avium</italic>) that were chosen for further investigation are denoted with blue text and an asterisk; (<bold>B</bold>) Alignment of human (h) IFITM3, mouse (m) IFITM3, hIFITM1, MAB IFITM, and MAV IFITM. Hydrophobic domain (HD) 1 is highlighted with a red bar and HD2 is highlighted with a green bar. The Yxx&#x003a6; motifs of hIFITM3 and mIFITM3 are shaded purple. Known <italic>S</italic>-palmitoylated cysteines in hIFITM3, mIFITM3, and hIFITM1, and potentially <italic>S</italic>-palmitoylated cysteines in MAB and MAV IFITMs are shaded red. Phenylalanines known to be involved in dimerization of IFITM3, and homologous phenylalanines in MAB and MAV IFITMs are shaded blue. The di-basic KRGY endocytic motif of hIFITM1 is shaded orange; (<bold>C</bold>) Amino acid percent identities as determined by Clustal alignment are shown comparing mycobacterial IFITMs with hIFITM3 or (<bold>D</bold>) hIFITM1. For (<bold>C</bold>) and (<bold>D</bold>), amino acid percent identities are also shown for mIFITM3 for comparison.</p></caption><graphic xlink:href="viruses-07-02759-g001"/></fig></sec><sec><title>3.2. Mycobacterial IFITMs Provide Antiviral Activity When Expressed in Human Cells</title><p>Given the important differences and striking similarities between the mycobacterial IFITMs and IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B), we sought to empirically determine if MAB and MAV IFITMs could confer antiviral activity when expressed in human cells. Since these IFITMs have never before been studied, antibodies for detection of their expression do not exist. Epitope tagging has been extensively used for the study of IFITMs [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>,<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B28-viruses-07-02759" ref-type="bibr">28</xref>,<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>,<xref rid="B30-viruses-07-02759" ref-type="bibr">30</xref>,<xref rid="B35-viruses-07-02759" ref-type="bibr">35</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>,<xref rid="B37-viruses-07-02759" ref-type="bibr">37</xref>,<xref rid="B38-viruses-07-02759" ref-type="bibr">38</xref>,<xref rid="B39-viruses-07-02759" ref-type="bibr">39</xref>,<xref rid="B40-viruses-07-02759" ref-type="bibr">40</xref>,<xref rid="B41-viruses-07-02759" ref-type="bibr">41</xref>], but it has been hypothesized that epitope tags may alter IFITM3 activity [<xref rid="B7-viruses-07-02759" ref-type="bibr">7</xref>,<xref rid="B8-viruses-07-02759" ref-type="bibr">8</xref>,<xref rid="B13-viruses-07-02759" ref-type="bibr">13</xref>], though data demonstrating this has not been published. Thus, we first examined N-terminally HA-tagged and untagged human IFITM3 expressed from the same vector for their ability to inhibit influenza virus infection of HEK293T cells. This human cell line was utilized for our studies because it is highly infectable and capable of supporting the full life cycle of influenza virus [<xref rid="B42-viruses-07-02759" ref-type="bibr">42</xref>], it expresses low levels of endogenous IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f002">Figure 2</xref>A,B), it is highly transfectable, and it has proved useful for distinguishing subtle differences in the activities of various IFITM mutants in several studies [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B9-viruses-07-02759" ref-type="bibr">9</xref>,<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B28-viruses-07-02759" ref-type="bibr">28</xref>,<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>,<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>]. HEK293T cells robustly expressed both HA-IFITM3 and IFITM3 as examined by Western blotting with anti-IFITM3 antibodies (<xref ref-type="fig" rid="viruses-07-02759-f002">Figure 2</xref>A). Analysis at the single cell level by flow cytometry confirmed that only a small percentage of HEK293T cells express detectable levels of endogenous IFITM3, and that our transfection efficiencies for the IFITM3 constructs were greater than 70% (<xref ref-type="fig" rid="viruses-07-02759-f002">Figure 2</xref>B). Compared to the vector control transfection, both HA-IFITM3 and IFITM3 were able to significantly inhibit infection by influenza A virus (IAV) H1N1 strain PR8 as measured by anti-IAV nucleoprotein staining by flow cytometry [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>]. No statistically significant difference was observed in the abilities of HA-IFITM3 and IFITM3 to inhibit infection (<xref ref-type="fig" rid="viruses-07-02759-f002">Figure 2</xref>C). Thus, we reasoned that utilization of HA-tagging of the mycobacterial IFITMs could provide an effective way to measure their expression without a likely effect on activity.</p><fig id="viruses-07-02759-f002" position="float"><label>Figure 2</label><caption><p>N-terminal HA-tagging of human IFITM3 does not affect its anti-influenza virus activity. (<bold>A</bold>) HEK293T cells were transfected with empty vector, or vector expressing human HA-IFITM3 or untagged human IFITM3. Cell lysates were examined by Western blotting with anti-IFITM3 antibodies and anti-GAPDH antibodies as a loading control; (<bold>B</bold>) Cells treated as in (<bold>A</bold>) were examined by flow cytometry staining with anti-IFITM3 antibodies. Cells are gated on IFITM3-positive cells and the blue numbers indicate the average of triplicate samples +/&#x02212; standard deviation. Ssc, side scatter; (<bold>C</bold>) Cells treated as in (<bold>A</bold>) and (<bold>B</bold>) were infected with IAV H1N1 strain PR8 at an MOI of 1.0 or mock infected for 6 h. Cells were analyzed for percent infection by flow cytometry based on anti-IAV nucleoprotein staining in comparison to mock-infected controls. Average percent infection of triplicate samples in a representative experiment was graphed. Error bars indicate standard deviation. Results are representative of more than 5 similar experiments. NS, not significant by Student&#x02019;s <italic>t</italic> test.</p></caption><graphic xlink:href="viruses-07-02759-g002"/></fig><p>We synthesized codon optimized MAB and MAV IFITM genes for insertion into the pCMV-HA mammalian expression vector in-frame with the HA tag of the vector, and transfected these constructs into HEK293T cells. After transfection, we observed high expression of MAB IFITM, far greater than IFITM3 expression from the same vector, and a more similar expression level of MAV IFITM (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>A). Thus, for infection experiments, we halved the amount of MAB IFITM plasmid utilized as compared to other plasmids, which provided a more comparable level of MAB IFITM (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>B). These transfected cells were infected with IAV H1N1 for examination of antiviral activity. As negative controls we utilized empty pCMV-HA vector and overexpression of murine HA-IRGM1, which has been reported to be involved in antibacterial immunity [<xref rid="B43-viruses-07-02759" ref-type="bibr">43</xref>,<xref rid="B44-viruses-07-02759" ref-type="bibr">44</xref>], but has not been reported to inhibit influenza virus infection. We also utilized human HA-IFITM3 as a positive control. At 6 h post infection, we measured the percent of infected cells in each transfection condition by anti-IAV nucleoprotein staining analysis by flow cytometry [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>]. As expected, HA-IRGM1 had no effect on infection as compared to the vector control, while HA-IFITM3 dramatically lowered the rate of infection (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>C). Remarkably, both HA-MAB IFITM and HA-MAV IFITM also both significantly lowered the percentage of infected cells, with HA-MAV IFITM showing a more potent ability to restrict infection, though neither mycobacterial protein was as effective as HA-IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>C). We also found that HA-MAB IFITM and HA-MAV IFITM were each able to inhibit infection by the IAV H3N2 strain X31 with similar efficacy to the inhibition of IAV H1N1 (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>D). We then examined the specificity of this antiviral response by measuring the effect of these proteins on Sendai virus (SeV), which fuses at the cell surface and is not strongly inhibited by the endolysosomal perturbations induced by IFITM3 [<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>]. Importantly, the infection rate of SeV was not dramatically affected by expression of any of the IFITMs, confirming specificity of the antiviral effect of mycobacterial IFITMs, and that these mycobacterial proteins are not inherently toxic to cells (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>D). Thus, the ability of the mycobacterial IFITMs to restrict IAV, along with the specificity of their virus restriction ability, identify MAB IFITM and MAV IFITM as functional homologues of IFITM3.</p><fig id="viruses-07-02759-f003" position="float"><label>Figure 3</label><caption><p>IFITMs from mycobacteria inhibit influenza virus infection when expressed in human cells. (<bold>A</bold>) HEK293T cells were transfected overnight with equal amounts empty vector or vector expressing human HA-IFITM3, HA-MAB IFITM3 or HA-MAV IFITM3. Lysates were analyzed by Western blotting with anti-HA antibody staining and anti-GAPDH staining as a loading control; (<bold>B</bold>) HEK293T cells were transfected overnight with equal amounts of empty vector, human HA-IFITM3, murine HA-IRGM1, or HA-MAV IFITM, or half the concentration of HA-MAB IFITM. Cell lysates were analyzed by Western blotting with anti-HA antibody staining and anti-GAPDH staining as a loading control; (<bold>C</bold>,<bold>D</bold>) Cells transfected as in <bold>B</bold> were infected with IAV H1N1 strain PR8 at an MOI of 2.5 or IAV H3N2 strain X31 or SeV at an MOI of 5.0. Cells were then collected and stained with anti-HA and anti-IAV nucleoprotein antibodies or anti-SeV antiserum. Cells were analyzed for percent infection by flow cytometry based on anti-IAV nucleoprotein or anti-SeV antibody staining in comparison to non-infected controls. The average percent infection for vector control cells was set to 1 for each infection. At least three independent experiments, each with triplicate measurements, were averaged and graphed. Error bars indicate standard errors of the means. <bold>*</bold>
<italic>p</italic> &#x0003c; 0.01 compared to vector control by Student&#x02019;s <italic>t</italic> test.</p></caption><graphic xlink:href="viruses-07-02759-g003"/></fig></sec><sec><title>3.3. Mycobacterial IFITMs Are S-Palmitoylated in Human Cells</title><p><italic>S</italic>-palmitoylation of IFITM3 is important for its proper membrane targeting and maximal antiviral activity [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B12-viruses-07-02759" ref-type="bibr">12</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>]. Using a fluorescence-based chemical reporter assay [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B21-viruses-07-02759" ref-type="bibr">21</xref>,<xref rid="B22-viruses-07-02759" ref-type="bibr">22</xref>,<xref rid="B23-viruses-07-02759" ref-type="bibr">23</xref>,<xref rid="B45-viruses-07-02759" ref-type="bibr">45</xref>,<xref rid="B46-viruses-07-02759" ref-type="bibr">46</xref>], we examined whether or not MAB and MAV IFITMs were also palmitoylated. Both HA-MAB IFITM and HA-MAV IFITM showed fluorescent palmitoylation signal above that of the vector control and a non-palmitoylated mutant of HA-IFITM3, which both served as negative controls (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A). However, both of the mycobacterial IFITMs showed lower palmitoylation signal than HA-IFITM3, and, given the high level of immunoprecipitated HA-MAB IFITM, which is seen as a large and partially smeared band, its low palmitoylation signal suggests that it is only weakly palmitoylated (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A). HA-MAV IFITM, which showed a moderate level of palmitoylation as compared to HA-IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A), possesses a di-cysteine motif at amino acid positions 37 and 38 that is homologous to known <italic>S</italic>-palmitoylation sites on IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). MAB IFITM possess only one cysteine at the C-terminal edge of its second hydrophobic domain (amino acid position 107, <xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B) that is reminiscent of a non-conserved <italic>S</italic>-palmitoylation site present on murine IFITM1 [<xref rid="B33-viruses-07-02759" ref-type="bibr">33</xref>]. Using cysteine-to-alanine mutagenesis, we confirmed that MAV IFITM cysteines 37 and 38, and MAB IFITM cysteine 107 are indeed required for <italic>S</italic>-palmitoylation of these IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>B). We next tested the ability of these mutants to inhibit influenza virus infection. As previously reported, the palmitoylation-deficient mutant of IFITM3 lost a significant portion of its antiviral activity as compared to wild type IFITM3 [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B34-viruses-07-02759" ref-type="bibr">34</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>] (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>C). Similarly, non-palmitoylated MAV IFITM also partially lost antiviral activity, further suggesting a common mechanism of antiviral action between MAV IFITM and IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>C). Consistent with the overall weak antiviral activity of MAB IFITM and its minimal <italic>S</italic>-palmitoylation (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A,B), mutation of cysteine 107 within this protein did not have a statistically significant effect on viral infection (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>C). Overall these results are consistent with the assertion that strong <italic>S</italic>-palmitoylation of IFITMs is a driver of maximal antiviral activity [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B12-viruses-07-02759" ref-type="bibr">12</xref>,<xref rid="B32-viruses-07-02759" ref-type="bibr">32</xref>].</p></sec><sec><title>3.4. MAV IFITM Co-Immunoprecipitates and Co-Localizes with IFITM3</title><p>IFITM3 was reported to homodimerize and also to heterodimerize with other IFITMs [<xref rid="B34-viruses-07-02759" ref-type="bibr">34</xref>,<xref rid="B47-viruses-07-02759" ref-type="bibr">47</xref>]. This dimerization was found to be dependent upon the presence of two phenylalanines within IFITM3&#x02019;s first hydrophobic domain [<xref rid="B34-viruses-07-02759" ref-type="bibr">34</xref>]. Mutation of either of these residues individually had little effect on dimerization or antiviral activity, but mutation of both residues eliminated dimerization and decreased antiviral activity [<xref rid="B34-viruses-07-02759" ref-type="bibr">34</xref>]. These results suggested that these two phenylalanines serve a redundant purpose and that IFITM dimerization promotes antiviral activity. Interestingly, both MAB and MAV IFITMs possess at least one of these phenylalanines conserved within their first hydrophobic domains (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). MAV-IFITM possesses one of these phenylalanines while MAB-IFITM possesses both. To provide evidence as to whether MAV IFITM might interact with IFITM3, we co-transfected HA-MAV IFITM with human myc-IFITM3 and examined their ability to co-immunoprecipate with one another. Indeed, we observed that MAV IFITM and IFITM3 co-precipitate (<xref ref-type="fig" rid="viruses-07-02759-f005">Figure 5</xref>A). Providing support for this finding that HA-MAV IFITM and IFITM3 may interact, HA-MAB IFITM and HA-MAV IFITM both strongly co-localize with Myc-IFITM3 in cells as visualized by confocal immunofluorescence microscopy (<xref ref-type="fig" rid="viruses-07-02759-f005">Figure 5</xref>B). Thus, the ability to interact may be a conserved aspect contributing to the functional homology between mycobacterial IFITMs and IFITM3.</p><fig id="viruses-07-02759-f004" position="float"><label>Figure 4</label><caption><p>Mycobacterial IFITMs are modestly <italic>S</italic>-palmitoylated when expressed in human cells. (<bold>A</bold>&#x02013;<bold>C</bold>) HEK293T cells were transfected overnight with the indicated murine HA-IFITM3 constructs or HA-tagged mycobacterial IFITM expression constructs or with empty vector control. (<bold>A</bold>,<bold>B</bold>) Cells were labeled for 1 h with 50 &#x003bc;M alk-16 or DMSO as a control and cell lysates were subjected to immunoprecipitation with anti-HA Affinity Gel prior to reaction with azido-rhodamine (az-rho) via click chemistry for fluorescence gel scanning in order to visualize levels of protein palmitoylation. Western blotting with anti-HA antibody was performed to allow comparison of protein loading. Data are representative of four experiments. <bold>*</bold> Denotes the antibody light chain used for immunoprecipitation that exhibits autofluorescence due to its high abundance; (<bold>C</bold>) Cells were infected for 6 h with IAV strain PR8 at an MOI of 2.5 and analyzed for percent infection by flow cytometry based on anti-IAV nucleoprotein staining in comparison to non-infected controls. The average percent infection of triplicate samples for a representative of three independent experiments was graphed. Error bars represent standard errors of the means. <bold>*</bold>
<italic>p</italic> &#x0003c; 0.01 by Student&#x02019;s <italic>t</italic> test comparing samples indicated by horizontal lines. NS, not significant by Student&#x02019;s <italic>t</italic> test.</p></caption><graphic xlink:href="viruses-07-02759-g004"/></fig><fig id="viruses-07-02759-f005" position="float"><label>Figure 5</label><caption><p>MAV IFITM co-immunoprecipitates and co-localizes with IFITM3. (<bold>A</bold>,<bold>B</bold>) HEK293T cells were transfected with the indicated constructs expressing HA-tagged mycobacterial IFITMs and human myc-IFITM3. (<bold>A</bold>) Cells were lysed and portions of the cell lysates were subjected to immunoprecipitation with either anti-HA or anti-myc Affinity Gel prior to SDS-PAGE and Western blot analysis with anti-HA or anti-myc antibodies. Western blotting of the cell lysates confirmed the equal input amounts of HA-MAV IFITM and the presence of myc-IFITM3; (<bold>B</bold>) Confocal microscopy imaging of mycobacterial IFITMs with myc-IFITM3 demonstrated their co-localization in cells. Anti-HA staining provided visualization of the mycobacterial IFITMs while anti-myc staining allowed visualization of IFITM3. DAPI staining was used to visualize nuclei. Merged images are shown with yellow regions indicating overlap between mycobacterial IFITMs and IFITM3.</p></caption><graphic xlink:href="viruses-07-02759-g005"/></fig></sec><sec><title>3.5. Mycobacterial IFITMs Partially Localize to Cathepsin B-Positive Cellular Compartments</title><p>IFITM3 has been reported to co-localize with early and late endosomal markers and with markers of lysosomes and multi-vesicular bodies [<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>,<xref rid="B9-viruses-07-02759" ref-type="bibr">9</xref>,<xref rid="B10-viruses-07-02759" ref-type="bibr">10</xref>,<xref rid="B11-viruses-07-02759" ref-type="bibr">11</xref>,<xref rid="B28-viruses-07-02759" ref-type="bibr">28</xref>,<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>,<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>,<xref rid="B48-viruses-07-02759" ref-type="bibr">48</xref>]. This localization is consistent with the ability of IFITM3 to prevent fusion of endocytosed influenza virus, and the subsequent degradation of the virus by lysosomal proteases [<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>,<xref rid="B11-viruses-07-02759" ref-type="bibr">11</xref>]. The strong localization of IFITM3 to endolysosomes is due in large measure to the presence of a Yxx&#x003a6; motif within its <italic>N</italic>-terminus that interacts with endocytic adaptor complexes, resulting in the effective trafficking of IFITM3 from the plasma membrane to endosomes [<xref rid="B20-viruses-07-02759" ref-type="bibr">20</xref>,<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>]. This motif is highly conserved in vertebrate IFITMs [<xref rid="B29-viruses-07-02759" ref-type="bibr">29</xref>], but is not present in the mycobacterial IFITMs, nor do they possess a sequence similar to the di-basic motif that directs the trafficking of human IFITM1 [<xref rid="B30-viruses-07-02759" ref-type="bibr">30</xref>] (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B). We examined the co-localization of IFITM3 and mycobacterial IFITMs with mEmerald-tagged cathepsin B, a lysosomal protease. As expected, IFITM3 showed extensive co-localization with cathepsin B (<xref ref-type="fig" rid="viruses-07-02759-f006">Figure 6</xref>A). MAB and MAV IFITMs also both showed strong co-localization with cathepsin B, but these IFITMs also localized to cathepsin B-negative compartments (<xref ref-type="fig" rid="viruses-07-02759-f006">Figure 6</xref>A). Quantification of the overlap of each of the IFITMs with cathepsin B confirmed a significant decrease in the co-localization of mycobacterial IFITMs with cathepsin B-positive compartments as compared to IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f006">Figure 6</xref>B). Our results may indicate that the strong co-localization seen between mycobacterial IFITMs and IFITM3 in <xref ref-type="fig" rid="viruses-07-02759-f005">Figure 5</xref>B is indeed due to an interaction between these proteins since mycobacterial IFITMs and IFITM3 do not localize to precisely the same compartments when expressed in isolation (<xref ref-type="fig" rid="viruses-07-02759-f006">Figure 6</xref>). These results are consistent with the lack of an IFITM1- or IFITM3-homologous endocytic targeting motif within the mycobacterial IFITM amino acid sequences (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B) and, along with the weak <italic>S</italic>-palmitoylation that we observed for mycobacterial IFITMs compared to IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A,B), this localization phenotype may contribute to the reduced antiviral activity of the mycobacterial IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>C,D and <xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>C).</p><fig id="viruses-07-02759-f006" position="float"><label>Figure 6</label><caption><p>Mycobacterial IFITMs localize to lysosomes less efficiently than IFITM3. (<bold>A</bold>,<bold>B</bold>) HEK293T cells grown on glass coverslips were transfected with expression plasmids encoding human HA-IFITM3, HA-MAB IFITM, or HA-MAV IFITM along with plasmid expressing mEmerald-Cathepsin B. (<bold>A</bold>) Confocal microscopy imaging of anti-HA staining, which provided visualization of the IFITMs, and mEmerald imaging, which provided visualization of the cathepsin-positive lysosomal compartment. DAPI staining was used to visualize nuclei. Merged images are shown with yellow regions indicating overlap between IFITMs and Cathepsin B; (<bold>B</bold>) The Manders overlap coefficient for each indicated IFITM with Cathepsin B was quantified for at least 20 individual cells as visualized in (<bold>A</bold>) from two independent experiments. The average value was graphed and error bars represent standard errors of the means. <bold>*</bold>
<italic>p</italic> &#x0003c; 0.0001 by Students <italic>t</italic> test compared to HA-IFITM3.</p></caption><graphic xlink:href="viruses-07-02759-g006"/></fig></sec></sec><sec><title>4. Discussion</title><p>Though the exact evolutionary origin of vertebrate IFITMs is unknown, an IFITM with a splicing pattern that is conserved in all metazoans was identified in <italic>Monosiga brevicollis</italic> [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>], a unicellular eukaryote considered to be the last unicellular ancestor of metazoans. This may suggest that IFITMs emerged in a common ancestor of metazoans and <italic>Monosiga brevicollis</italic>. IFITMs were also identified in multiple ancient bacteria species, and given the identifiable sequence similarities between bacterial IFITMs and metazoan IFITMs (<xref ref-type="fig" rid="viruses-07-02759-f001">Figure 1</xref>B), it was hypothesized that a horizontal gene transfer from bacteria introduced an IFITM gene into the single-celled metazoan ancestor discussed above [<xref rid="B19-viruses-07-02759" ref-type="bibr">19</xref>]. Here, we chose two divergent bacterial IFITMs for introduction into human HEK293T cells. Both MAB and MAV IFITMs conferred enhanced resistance to influenza virus infection as compared to control transfections (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>C,D). Confirming that the activity of these proteins is functionally homologous to IFITM3, these proteins, similarly to IFITM3, were unable to inhibit SeV infection (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>D), and their level of activity correlated with their level of <italic>S</italic>-palmitoylation (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>), which is a known positive regulatory modification of IFITM3 [<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B12-viruses-07-02759" ref-type="bibr">12</xref>]. The functional homology of the bacterial IFITMs with IFITM3 could indicate that transfer of a bacterial IFITM to eukaryotes offered an advantage against virus infection that was refined through co-evolution with viruses. This hypothesis is in line with emerging data that IFITMs are antiviral in all animal species that have been tested and reported on to date [<xref rid="B1-viruses-07-02759" ref-type="bibr">1</xref>,<xref rid="B2-viruses-07-02759" ref-type="bibr">2</xref>,<xref rid="B3-viruses-07-02759" ref-type="bibr">3</xref>,<xref rid="B4-viruses-07-02759" ref-type="bibr">4</xref>,<xref rid="B5-viruses-07-02759" ref-type="bibr">5</xref>,<xref rid="B6-viruses-07-02759" ref-type="bibr">6</xref>]. This information also now provides a platform for examination of critical amino acid determinants of IFITM3 biology as discussed below.</p><p>Many aspects of IFITM3 cell biology that are not fully understood may possibly be clarified by study of the mycobacterial IFITMs. For example, IFITM3 is known to be optimally active when expressed at high levels in cells, and its turnover is promoted by post-translational ubiquitination [<xref rid="B36-viruses-07-02759" ref-type="bibr">36</xref>]. However, we do not have a clear knowledge of the aspects of IFITM3 that control its cellular levels and ubiquitination. MAB IFITM was expressed at higher levels than MAV IFITM or IFITM3 when using the same amount of plasmid for transfections (<xref ref-type="fig" rid="viruses-07-02759-f003">Figure 3</xref>A). Thus, it will be interesting to determine what features of MAB IFITM allow its robust accumulation and whether or not it avoids ubiquitination and degradation. Such information may inspire strategies for increasing IFITM3 levels for the purpose of improving virus resistance. Likewise, despite possessing a di-cysteine motif in its first hydrophobic domain, MAV IFITM was less robustly palmitoylated than IFITM3 (<xref ref-type="fig" rid="viruses-07-02759-f004">Figure 4</xref>A,B). Interestingly, the MAV IFITM di-cysteine motif is shifted three positions deeper within the first hydrophobic domain compared to its location within IFITM3, and this is also true for most of the other mycobacterial IFITMs that possess the di-cysteine motif. This may suggest that the positioning of the di-cysteine motif within the hydrophobic domain is a critical determinant of its <italic>S</italic>-palmitoylation level and that positioning of this domain evolved toward optimal modification in vertebrates. Alternatively, other determinants may affect interaction with the as yet unidentified palmitoyltransferase enzyme that modifies IFITMs. Further interrogation of MAV IFITM may shed light on these important questions.</p><p>The precise mechanism of antiviral action of IFITMs is also currently unknown. Two potentially complementary models have been proposed for the anti-influenza virus activity of IFITM3. One, IFITM3 may directly alter fluidity of endolysosomal membranes [<xref rid="B9-viruses-07-02759" ref-type="bibr">9</xref>,<xref rid="B10-viruses-07-02759" ref-type="bibr">10</xref>,<xref rid="B49-viruses-07-02759" ref-type="bibr">49</xref>] through the insertion of its intramembrane domain (the first hydrophobic domain) [<xref rid="B12-viruses-07-02759" ref-type="bibr">12</xref>], and two, IFITM3 may alter membrane cholesterol levels by interacting with VAPA, a protein involved in cholesterol homeostasis [<xref rid="B37-viruses-07-02759" ref-type="bibr">37</xref>]. Determining whether the mycobacterial IFITMs adopt an intramembrane topology or interact with VAPA may aid in distinguishing the importance of these two proposed models for IFITM3 antiviral activity. Beyond inhibition of viral entry, vertebrate IFITMs have also been suggested to inhibit HIV-1 by limiting virus replication [<xref rid="B38-viruses-07-02759" ref-type="bibr">38</xref>,<xref rid="B39-viruses-07-02759" ref-type="bibr">39</xref>], and by incorporating into newly produced virions leading to decreased infectivity [<xref rid="B40-viruses-07-02759" ref-type="bibr">40</xref>,<xref rid="B41-viruses-07-02759" ref-type="bibr">41</xref>]. Conversely, particular IFITMs have been reported to facilitate the cellular entry of a specific coronavirus [<xref rid="B50-viruses-07-02759" ref-type="bibr">50</xref>]. It will be interesting to determine whether these additional functions of vertebrate IFITMs are shared by the mycobacterial IFITMs. Overall, we have identified two bacterial IFITMs as functional homologues of IFITM3, noted important similarities and differences between these proteins and IFITM3, and propose that further study of these proteins will provide greater understanding of IFITM3 post-translational regulation and antiviral activity.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by NIH/NIAID grants R00AI095348 and R56AI114826 to J.S.Y., and by the Ohio State University Public Health Preparedness for Infectious Diseases (PHPID) program. N.M.C. is supported by the Ohio State University Systems and Integrative Biology Training Program (NIH/NIGMS grant T32GM068412) and T.M.M. is supported by the American Society for Microbiology Robert D. Watkins Graduate Research Fellowship. W.J.M. was supported by a Roessler Memorial Scholarship for Medical Student Research through the OSU College of Medicine.</p></ack><notes><title>Author Contributions</title><p>Cloning was performed by W.J.M, and N.M.C. Initial infection experiments were performed by W.J.M. and experimental repeats were performed by T.M.M., J.C.H., and J.S.Y. Palmitoylation experiments were performed by W.J.M and N.M.C, and other biochemical experiments were performed by T.M.M. Confocal Imaging and quantification was performed by W.J.M. The research was supervised by J.S.Y., and the manuscript was written by J.S.Y. and T.M.M. with editorial contributions from all other authors.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-07-02759"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Gibson</surname><given-names>M.S.</given-names></name><name><surname>Wash</surname><given-names>R.S.</given-names></name><name><surname>Ferrara</surname><given-names>F.</given-names></name><name><surname>Wright</surname><given-names>E.</given-names></name><name><surname>Temperton</surname><given-names>N.</given-names></name><name><surname>Kellam</surname><given-names>P.</given-names></name><name><surname>Fife</surname><given-names>M.</given-names></name></person-group>
<article-title>Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses <italic>in vitro</italic></article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>12957</fpage>
<lpage>12966</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01443-13</pub-id>
<pub-id pub-id-type="pmid">24067955</pub-id></element-citation></ref><ref id="B2-viruses-07-02759"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lei</surname><given-names>X.Y.</given-names></name><name><surname>Gui</surname><given-names>J.F.</given-names></name><name><surname>Zhang</surname><given-names>Q.Y.</given-names></name></person-group>
<article-title>Evidence for paralichthys olivaceus IFITM1 antiviral effect by impeding viral entry into target cells</article-title>
<source>Fish Shellfish Immun.</source>
<year>2013</year>
<volume>35</volume>
<fpage>918</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="doi">10.1016/j.fsi.2013.07.002</pub-id>
<pub-id pub-id-type="pmid">23850425</pub-id></element-citation></ref><ref id="B3-viruses-07-02759"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benfield</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Wright</surname><given-names>E.</given-names></name><name><surname>Wash</surname><given-names>R.S.</given-names></name><name><surname>Ferrara</surname><given-names>F.</given-names></name><name><surname>Temperton</surname><given-names>N.J.</given-names></name><name><surname>Kellam</surname><given-names>P.</given-names></name></person-group>
<article-title>Bat and pig interferon-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses</article-title>
<source>J. Gen. Virol.</source>
<year>2015</year>
<volume>96</volume>
<fpage>991</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="doi">10.1099/vir.0.000058</pub-id>
<pub-id pub-id-type="pmid">25614588</pub-id></element-citation></ref><ref id="B4-viruses-07-02759"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Moltedo</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>Y.Y.</given-names></name><name><surname>Charron</surname><given-names>G.</given-names></name><name><surname>Moran</surname><given-names>T.M.</given-names></name><name><surname>Lopez</surname><given-names>C.B.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Palmitoylome profiling reveals <italic>S</italic>-palmitoylation-dependent antiviral activity of IFITM3</article-title>
<source>Nat. Chem. Biol.</source>
<year>2010</year>
<volume>6</volume>
<fpage>610</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio.405</pub-id>
<pub-id pub-id-type="pmid">20601941</pub-id></element-citation></ref><ref id="B5-viruses-07-02759"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brass</surname><given-names>A.L.</given-names></name><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Benita</surname><given-names>Y.</given-names></name><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Krishnan</surname><given-names>M.N.</given-names></name><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Ryan</surname><given-names>B.J.</given-names></name><name><surname>Weyer</surname><given-names>J.L.</given-names></name><name><surname>van der Weyden</surname><given-names>L.</given-names></name><name><surname>Fikrig</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>The IFITM proteins mediate cellular resistance to influenza a H1N1 virus, west nile virus, and dengue virus</article-title>
<source>Cell</source>
<year>2009</year>
<volume>139</volume>
<fpage>1243</fpage>
<lpage>1254</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.12.017</pub-id>
<pub-id pub-id-type="pmid">20064371</pub-id></element-citation></ref><ref id="B6-viruses-07-02759"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Bailey</surname><given-names>C.C.</given-names></name><name><surname>Weyer</surname><given-names>J.L.</given-names></name><name><surname>Radoshitzky</surname><given-names>S.R.</given-names></name><name><surname>Becker</surname><given-names>M.M.</given-names></name><name><surname>Chiang</surname><given-names>J.J.</given-names></name><name><surname>Brass</surname><given-names>A.L.</given-names></name><name><surname>Ahmed</surname><given-names>A.A.</given-names></name><name><surname>Chi</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza a virus</article-title>
<source>PLoS Pathog.</source>
<year>2011</year>
<volume>7</volume>
<fpage>e1001258</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1001258</pub-id>
<pub-id pub-id-type="pmid">21253575</pub-id></element-citation></ref><ref id="B7-viruses-07-02759"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Weston</surname><given-names>S.</given-names></name><name><surname>Kellam</surname><given-names>P.</given-names></name><name><surname>Marsh</surname><given-names>M.</given-names></name></person-group>
<article-title>IFITM proteins-cellular inhibitors of viral entry</article-title>
<source>Curr. Opin. Virol.</source>
<year>2014</year>
<volume>4C</volume>
<fpage>71</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.coviro.2013.11.004</pub-id>
<pub-id pub-id-type="pmid">24480526</pub-id></element-citation></ref><ref id="B8-viruses-07-02759"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perreira</surname><given-names>J.M.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Brass</surname><given-names>A.L.</given-names></name></person-group>
<article-title>IFITMs restrict the replication of multiple pathogenic viruses</article-title>
<source>J. Mol. Biol.</source>
<year>2013</year>
<volume>425</volume>
<fpage>4937</fpage>
<lpage>4955</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2013.09.024</pub-id>
<pub-id pub-id-type="pmid">24076421</pub-id></element-citation></ref><ref id="B9-viruses-07-02759"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Markosyan</surname><given-names>R.M.</given-names></name><name><surname>Zheng</surname><given-names>Y.M.</given-names></name><name><surname>Golfetto</surname><given-names>O.</given-names></name><name><surname>Bungart</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>J.C.</given-names></name><etal/></person-group>
<article-title>IFITM proteins restrict viral membrane hemifusion</article-title>
<source>PLoS Pathog.</source>
<year>2013</year>
<volume>9</volume>
<fpage>e1003124</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1003124</pub-id>
<pub-id pub-id-type="pmid">23358889</pub-id></element-citation></ref><ref id="B10-viruses-07-02759"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desai</surname><given-names>T.M.</given-names></name><name><surname>Marin</surname><given-names>M.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Savidis</surname><given-names>G.</given-names></name><name><surname>Brass</surname><given-names>A.L.</given-names></name><name><surname>Melikyan</surname><given-names>G.B.</given-names></name></person-group>
<article-title>IFITM3 restricts influenza a virus entry by blocking the formation of fusion pores following virus-endosome hemifusion</article-title>
<source>PLoS Pathog.</source>
<year>2014</year>
<volume>10</volume>
<fpage>e1004048</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1004048</pub-id>
<pub-id pub-id-type="pmid">24699674</pub-id></element-citation></ref><ref id="B11-viruses-07-02759"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Sims</surname><given-names>J.S.</given-names></name><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Pertel</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>L.M.</given-names></name><name><surname>Gaiha</surname><given-names>G.D.</given-names></name><name><surname>Ryan</surname><given-names>B.J.</given-names></name><name><surname>Donis</surname><given-names>R.O.</given-names></name><name><surname>Elledge</surname><given-names>S.J.</given-names></name><etal/></person-group>
<article-title>IFITM3 inhibits influenza a virus infection by preventing cytosolic entry</article-title>
<source>PLoS Pathog.</source>
<year>2011</year>
<volume>7</volume>
<fpage>e1002337</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1002337</pub-id>
<pub-id pub-id-type="pmid">22046135</pub-id></element-citation></ref><ref id="B12-viruses-07-02759"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chesarino</surname><given-names>N.M.</given-names></name><name><surname>McMichael</surname><given-names>T.M.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications</article-title>
<source>Future Microbiol.</source>
<year>2014</year>
<volume>9</volume>
<fpage>1151</fpage>
<lpage>1163</lpage>
<pub-id pub-id-type="doi">10.2217/fmb.14.65</pub-id>
<pub-id pub-id-type="pmid">25405885</pub-id></element-citation></ref><ref id="B13-viruses-07-02759"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bailey</surname><given-names>C.C.</given-names></name><name><surname>Zhong</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group>
<article-title>IFITM-family proteins: The cell&#x02019;s first line of antiviral defense</article-title>
<source>Annu. Rev. Virol.</source>
<year>2014</year>
<volume>1</volume>
<fpage>261</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-virology-031413-085537</pub-id>
<pub-id pub-id-type="pmid">25599080</pub-id></element-citation></ref><ref id="B14-viruses-07-02759"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Everitt</surname><given-names>A.R.</given-names></name><name><surname>Clare</surname><given-names>S.</given-names></name><name><surname>Pertel</surname><given-names>T.</given-names></name><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Wash</surname><given-names>R.S.</given-names></name><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Sims</surname><given-names>J.S.</given-names></name><name><surname>Adams</surname><given-names>D.J.</given-names></name><etal/></person-group>
<article-title>IFITM3 restricts the morbidity and mortality associated with influenza</article-title>
<source>Nature</source>
<year>2012</year>
<volume>484</volume>
<fpage>519</fpage>
<lpage>523</lpage>
<pub-id pub-id-type="doi">10.1038/nature10921</pub-id>
<pub-id pub-id-type="pmid">22446628</pub-id></element-citation></ref><ref id="B15-viruses-07-02759"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bailey</surname><given-names>C.C.</given-names></name><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Kam</surname><given-names>C.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group>
<article-title>IFITM3 limits the severity of acute influenza in mice</article-title>
<source>PLoS Pathog.</source>
<year>2012</year>
<volume>8</volume>
<fpage>e1002909</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1002909</pub-id>
<pub-id pub-id-type="pmid">22969429</pub-id></element-citation></ref><ref id="B16-viruses-07-02759"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Qiu</surname><given-names>C.</given-names></name><name><surname>Xi</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2013</year>
<volume>111</volume>
<fpage>769</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1321748111</pub-id>
<pub-id pub-id-type="pmid">24367104</pub-id></element-citation></ref><ref id="B17-viruses-07-02759"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Peng</surname><given-names>Y.C.</given-names></name><name><surname>Giannoulatou</surname><given-names>E.</given-names></name><name><surname>Jin</surname><given-names>R.H.</given-names></name><name><surname>Yan</surname><given-names>H.P.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.H.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in chinese individuals</article-title>
<source>Nat. Commun.</source>
<year>2013</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1038/ncomms2433</pub-id>
<pub-id pub-id-type="pmid">23361009</pub-id></element-citation></ref><ref id="B18-viruses-07-02759"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xuan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.N.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zi</surname><given-names>H.R.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>W.J.</given-names></name><name><surname>Chen</surname><given-names>X.B.</given-names></name><name><surname>Wei</surname><given-names>P.M.</given-names></name></person-group>
<article-title>IFITM3 rs12252 T&#x0003e;C polymorphism is associated with the risk of severe influenza: A meta-analysis</article-title>
<source>Epidemiol. Infect.</source>
<year>2015</year>
<volume>17</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1017/S0950268815000278</pub-id>
<pub-id pub-id-type="pmid">25778715</pub-id></element-citation></ref><ref id="B19-viruses-07-02759"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sallman Almen</surname><given-names>M.</given-names></name><name><surname>Bringeland</surname><given-names>N.</given-names></name><name><surname>Fredriksson</surname><given-names>R.</given-names></name><name><surname>Schioth</surname><given-names>H.B.</given-names></name></person-group>
<article-title>The dispanins: A novel gene family of ancient origin that contains 14 human members</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<fpage>e31961</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0031961</pub-id>
<pub-id pub-id-type="pmid">22363774</pub-id></element-citation></ref><ref id="B20-viruses-07-02759"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chesarino</surname><given-names>N.M.</given-names></name><name><surname>McMichael</surname><given-names>T.M.</given-names></name><name><surname>Hach</surname><given-names>J.C.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Phosphorylation of the antiviral protein IFITM3 dually regulates its endocytosis and ubiquitination</article-title>
<source>J. Biol. Chem.</source>
<year>2014</year>
<volume>289</volume>
<fpage>11986</fpage>
<lpage>11992</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.557694</pub-id>
<pub-id pub-id-type="pmid">24627473</pub-id></element-citation></ref><ref id="B21-viruses-07-02759"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chesarino</surname><given-names>N.M.</given-names></name><name><surname>Hach</surname><given-names>J.C.</given-names></name><name><surname>Chen</surname><given-names>J.L.</given-names></name><name><surname>Zaro</surname><given-names>B.W.</given-names></name><name><surname>Rajaram</surname><given-names>M.V.</given-names></name><name><surname>Turner</surname><given-names>J.</given-names></name><name><surname>Schlesinger</surname><given-names>L.S.</given-names></name><name><surname>Pratt</surname><given-names>M.R.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Chemoproteomics reveals toll-like receptor fatty acylation</article-title>
<source>BMC Biol.</source>
<year>2014</year>
<volume>12</volume>
<fpage>91</fpage>
<pub-id pub-id-type="doi">10.1186/s12915-014-0091-3</pub-id>
<pub-id pub-id-type="pmid">25371237</pub-id></element-citation></ref><ref id="B22-viruses-07-02759"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Zhang</surname><given-names>M.M.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Visualization and identification of fatty acylated proteins using chemical reporters</article-title>
<source>Curr. Protoc. Chem. Biol.</source>
<year>2011</year>
<volume>3</volume>
<fpage>65</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">23061028</pub-id></element-citation></ref><ref id="B23-viruses-07-02759"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Charron</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>M.M.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><name><surname>Raghavan</surname><given-names>A.S.</given-names></name><name><surname>Shamir</surname><given-names>E.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Robust fluorescent detection of protein fatty-acylation with chemical reporters</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2009</year>
<volume>131</volume>
<fpage>4967</fpage>
<lpage>4975</lpage>
<pub-id pub-id-type="doi">10.1021/ja810122f</pub-id>
<pub-id pub-id-type="pmid">19281244</pub-id></element-citation></ref><ref id="B24-viruses-07-02759"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moltedo</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Moran</surname><given-names>T.M.</given-names></name></person-group>
<article-title>Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection</article-title>
<source>PLoS Pathog.</source>
<year>2011</year>
<volume>7</volume>
<fpage>e1002345</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1002345</pub-id>
<pub-id pub-id-type="pmid">22072965</pub-id></element-citation></ref><ref id="B25-viruses-07-02759"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Kraus</surname><given-names>T.A.</given-names></name><name><surname>Horvath</surname><given-names>C.M.</given-names></name><name><surname>Moran</surname><given-names>T.M.</given-names></name><name><surname>Lopez</surname><given-names>C.B.</given-names></name></person-group>
<article-title>A novel role for viral-defective interfering particles in enhancing dendritic cell maturation</article-title>
<source>J. Immunol.</source>
<year>2006</year>
<volume>177</volume>
<fpage>4503</fpage>
<lpage>4513</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4503</pub-id>
<pub-id pub-id-type="pmid">16982887</pub-id></element-citation></ref><ref id="B26-viruses-07-02759"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>C.Y.</given-names></name></person-group>
<article-title>Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<fpage>e49265</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0049265</pub-id>
<pub-id pub-id-type="pmid">23166625</pub-id></element-citation></ref><ref id="B27-viruses-07-02759"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hickford</surname><given-names>D.</given-names></name><name><surname>Frankenberg</surname><given-names>S.</given-names></name><name><surname>Shaw</surname><given-names>G.</given-names></name><name><surname>Renfree</surname><given-names>M.B.</given-names></name></person-group>
<article-title>Evolution of vertebrate interferon inducible transmembrane proteins</article-title>
<source>BMC Genomics</source>
<year>2012</year>
<volume>13</volume>
<pub-id pub-id-type="doi">10.1186/1471-2164-13-155</pub-id>
<pub-id pub-id-type="pmid">22537233</pub-id></element-citation></ref><ref id="B28-viruses-07-02759"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Pan</surname><given-names>Q.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><name><surname>Rong</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.L.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>W.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name></person-group>
<article-title>The <italic>N</italic>-terminal region of IFITM3 modulates its antiviral activity by regulating ifitm3 cellular localization</article-title>
<source>J. Virol.</source>
<year>2012</year>
<volume>86</volume>
<fpage>13697</fpage>
<lpage>13707</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01828-12</pub-id>
<pub-id pub-id-type="pmid">23055554</pub-id></element-citation></ref><ref id="B29-viruses-07-02759"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Miao</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>Y.M.</given-names></name><name><surname>Liu</surname><given-names>S.L.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>W.</given-names></name><etal/></person-group>
<article-title>Identification of an endocytic signal essential for the antiviral action of ifitm3</article-title>
<source>Cell. Microbiol.</source>
<year>2014</year>
<volume>16</volume>
<fpage>1080</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1111/cmi.12262</pub-id>
<pub-id pub-id-type="pmid">24521078</pub-id></element-citation></ref><ref id="B30-viruses-07-02759"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Miao</surname><given-names>C.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>W.</given-names></name><name><surname>Albritton</surname><given-names>L.M.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>A sorting signal suppresses ifitm1 restriction of viral entry</article-title>
<source>J. Biol. Chem.</source>
<year>2015</year>
<volume>290</volume>
<fpage>4248</fpage>
<lpage>4259</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.630780</pub-id>
<pub-id pub-id-type="pmid">25527505</pub-id></element-citation></ref><ref id="B31-viruses-07-02759"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M.S.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name></person-group>
<article-title>The broad-spectrum antiviral functions of ifit and ifitm proteins</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2013</year>
<volume>13</volume>
<fpage>46</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1038/nri3344</pub-id>
<pub-id pub-id-type="pmid">23237964</pub-id></element-citation></ref><ref id="B32-viruses-07-02759"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Zhang</surname><given-names>M.M.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Emerging roles for protein <italic>S</italic>-palmitoylation in immunity from chemical proteomics</article-title>
<source>Curr. Opin. Chem. Biol.</source>
<year>2013</year>
<volume>17</volume>
<fpage>27</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbpa.2012.11.008</pub-id>
<pub-id pub-id-type="pmid">23332315</pub-id></element-citation></ref><ref id="B33-viruses-07-02759"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hach</surname><given-names>J.C.</given-names></name><name><surname>McMichael</surname><given-names>T.</given-names></name><name><surname>Chesarino</surname><given-names>N.M.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name></person-group>
<article-title>Palmitoylation on conserved and non-conserved cysteines of murine IFITM1 regulates its stability and anti-influenza a virus activity</article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>9923</fpage>
<lpage>9927</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00621-13</pub-id>
<pub-id pub-id-type="pmid">23804635</pub-id></element-citation></ref><ref id="B34-viruses-07-02759"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Perreira</surname><given-names>J.M.</given-names></name><name><surname>Feeley</surname><given-names>E.M.</given-names></name><name><surname>Aker</surname><given-names>A.M.</given-names></name><name><surname>Savidis</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Elia</surname><given-names>A.E.</given-names></name><name><surname>Everitt</surname><given-names>A.R.</given-names></name><name><surname>Vora</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication</article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>7837</fpage>
<lpage>7852</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00481-13</pub-id>
<pub-id pub-id-type="pmid">23658454</pub-id></element-citation></ref><ref id="B35-viruses-07-02759"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weidner</surname><given-names>J.M.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Pan</surname><given-names>X.B.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Block</surname><given-names>T.M.</given-names></name><name><surname>Guo</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Interferon-induced cell membrane proteins, ifitm3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms</article-title>
<source>J. Virol.</source>
<year>2010</year>
<volume>84</volume>
<fpage>12646</fpage>
<lpage>12657</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01328-10</pub-id>
<pub-id pub-id-type="pmid">20943977</pub-id></element-citation></ref><ref id="B36-viruses-07-02759"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Karssemeijer</surname><given-names>R.A.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title><italic>S</italic>-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus</article-title>
<source>J. Biol. Chem.</source>
<year>2012</year>
<volume>287</volume>
<fpage>19631</fpage>
<lpage>19641</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.362095</pub-id>
<pub-id pub-id-type="pmid">22511783</pub-id></element-citation></ref><ref id="B37-viruses-07-02759"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amini-Bavil-Olyaee</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Jung</surname><given-names>J.U.</given-names></name></person-group>
<article-title>The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry</article-title>
<source>Cell Host Microbe</source>
<year>2013</year>
<volume>13</volume>
<fpage>452</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2013.03.006</pub-id>
<pub-id pub-id-type="pmid">23601107</pub-id></element-citation></ref><ref id="B38-viruses-07-02759"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>Q.</given-names></name><name><surname>Rong</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.L.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name></person-group>
<article-title>The IFITM proteins inhibit HIV-1 infection</article-title>
<source>J. Virol.</source>
<year>2011</year>
<volume>85</volume>
<fpage>2126</fpage>
<lpage>2137</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01531-10</pub-id>
<pub-id pub-id-type="pmid">21177806</pub-id></element-citation></ref><ref id="B39-viruses-07-02759"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chutiwitoonchai</surname><given-names>N.</given-names></name><name><surname>Hiyoshi</surname><given-names>M.</given-names></name><name><surname>Hiyoshi-Yoshidomi</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Tokunaga</surname><given-names>K.</given-names></name><name><surname>Suzu</surname><given-names>S.</given-names></name></person-group>
<article-title>Characteristics of IFITM, the newly identified ifn-inducible anti-HIV-1 family proteins</article-title>
<source>Microbes Infect.</source>
<year>2013</year>
<volume>15</volume>
<fpage>280</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1016/j.micinf.2012.12.003</pub-id>
<pub-id pub-id-type="pmid">23376165</pub-id></element-citation></ref><ref id="B40-viruses-07-02759"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tartour</surname><given-names>K.</given-names></name><name><surname>Appourchaux</surname><given-names>R.</given-names></name><name><surname>Gaillard</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>X.N.</given-names></name><name><surname>Durand</surname><given-names>S.</given-names></name><name><surname>Turpin</surname><given-names>J.</given-names></name><name><surname>Beaumont</surname><given-names>E.</given-names></name><name><surname>Roch</surname><given-names>E.</given-names></name><name><surname>Berger</surname><given-names>G.</given-names></name><name><surname>Mahieux</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity</article-title>
<source>Retrovirology</source>
<year>2014</year>
<volume>11</volume>
<fpage>103</fpage>
<pub-id pub-id-type="doi">10.1186/s12977-014-0103-y</pub-id>
<pub-id pub-id-type="pmid">25422070</pub-id></element-citation></ref><ref id="B41-viruses-07-02759"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Compton</surname><given-names>A.A.</given-names></name><name><surname>Bruel</surname><given-names>T.</given-names></name><name><surname>Porrot</surname><given-names>F.</given-names></name><name><surname>Mallet</surname><given-names>A.</given-names></name><name><surname>Sachse</surname><given-names>M.</given-names></name><name><surname>Euvrard</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Casartelli</surname><given-names>N.</given-names></name><name><surname>Schwartz</surname><given-names>O.</given-names></name></person-group>
<article-title>IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread</article-title>
<source>Cell Host Microbe</source>
<year>2014</year>
<volume>16</volume>
<fpage>736</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2014.11.001</pub-id>
<pub-id pub-id-type="pmid">25464829</pub-id></element-citation></ref><ref id="B42-viruses-07-02759"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T.</given-names></name><name><surname>Kawakami</surname><given-names>E.</given-names></name><name><surname>Shoemaker</surname><given-names>J.E.</given-names></name><name><surname>Lopes</surname><given-names>T.J.</given-names></name><name><surname>Matsuoka</surname><given-names>Y.</given-names></name><name><surname>Tomita</surname><given-names>Y.</given-names></name><name><surname>Kozuka-Hata</surname><given-names>H.</given-names></name><name><surname>Gorai</surname><given-names>T.</given-names></name><name><surname>Kuwahara</surname><given-names>T.</given-names></name><name><surname>Takeda</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>Influenza virus-host interactome screen as a platform for antiviral drug development</article-title>
<source>Cell Host Microbe</source>
<year>2014</year>
<volume>16</volume>
<fpage>795</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2014.11.002</pub-id>
<pub-id pub-id-type="pmid">25464832</pub-id></element-citation></ref><ref id="B43-viruses-07-02759"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.B.</given-names></name><name><surname>Davis</surname><given-names>A.S.</given-names></name><name><surname>Taylor</surname><given-names>G.A.</given-names></name><name><surname>Deretic</surname><given-names>V.</given-names></name></person-group>
<article-title>Human irgm induces autophagy to eliminate intracellular mycobacteria</article-title>
<source>Science</source>
<year>2006</year>
<volume>313</volume>
<fpage>1438</fpage>
<lpage>1441</lpage>
<pub-id pub-id-type="doi">10.1126/science.1129577</pub-id>
<pub-id pub-id-type="pmid">16888103</pub-id></element-citation></ref><ref id="B44-viruses-07-02759"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>H.P.</given-names></name><name><surname>Matsuzawa</surname><given-names>T.</given-names></name><name><surname>Pypaert</surname><given-names>M.</given-names></name><name><surname>MacMicking</surname><given-names>J.D.</given-names></name></person-group>
<article-title>Targeting of the gtpase irgm1 to the phagosomal membrane via ptdins(3,4)p-2 and ptdins(3,4,5)p-3 promotes immunity to mycobacteria</article-title>
<source>Nat. Immunol.</source>
<year>2009</year>
<volume>10</volume>
<fpage>907</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="doi">10.1038/ni.1759</pub-id>
<pub-id pub-id-type="pmid">19620982</pub-id></element-citation></ref><ref id="B45-viruses-07-02759"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Charron</surname><given-names>G.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Bioorthogonal proteomics of 15-hexadecynyloxyacetic acid chemical reporter reveals preferential targeting of fatty acid modified proteins and biosynthetic enzymes</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2012</year>
<volume>20</volume>
<fpage>650</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2011.03.062</pub-id>
<pub-id pub-id-type="pmid">21524915</pub-id></element-citation></ref><ref id="B46-viruses-07-02759"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Charron</surname><given-names>G.</given-names></name><name><surname>Tsou</surname><given-names>L.K.</given-names></name><name><surname>Maguire</surname><given-names>W.</given-names></name><name><surname>Yount</surname><given-names>J.S.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Alkynyl-farnesol reporters for detection of protein <italic>S</italic>-prenylation in cells</article-title>
<source>Mol. Biosyst.</source>
<year>2011</year>
<volume>7</volume>
<fpage>67</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1039/C0MB00183J</pub-id>
<pub-id pub-id-type="pmid">21107478</pub-id></element-citation></ref><ref id="B47-viruses-07-02759"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>T.</given-names></name><name><surname>Hang</surname><given-names>H.C.</given-names></name></person-group>
<article-title>Bifunctional fatty acid chemical reporter for analyzing <italic>S</italic>-palmitoylated membrane protein-protein interactions in mammalian cells</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2015</year>
<volume>137</volume>
<fpage>556</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1021/ja502109n</pub-id>
<pub-id pub-id-type="pmid">25575299</pub-id></element-citation></ref><ref id="B48-viruses-07-02759"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wee</surname><given-names>Y.S.</given-names></name><name><surname>Roundy</surname><given-names>K.M.</given-names></name><name><surname>Weis</surname><given-names>J.J.</given-names></name><name><surname>Weis</surname><given-names>J.H.</given-names></name></person-group>
<article-title>Interferon-inducible transmembrane proteins of the innate immune response act as membrane organizers by influencing clathrin and V-atpase localization and function</article-title>
<source>Innate Immun.</source>
<year>2012</year>
<volume>18</volume>
<fpage>834</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.1177/1753425912443392</pub-id>
<pub-id pub-id-type="pmid">22467717</pub-id></element-citation></ref><ref id="B49-viruses-07-02759"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>T.Y.</given-names></name><name><surname>Chin</surname><given-names>C.R.</given-names></name><name><surname>Everitt</surname><given-names>A.R.</given-names></name><name><surname>Clare</surname><given-names>S.</given-names></name><name><surname>Perreira</surname><given-names>J.M.</given-names></name><name><surname>Savidis</surname><given-names>G.</given-names></name><name><surname>Aker</surname><given-names>A.M.</given-names></name><name><surname>John</surname><given-names>S.P.</given-names></name><name><surname>Sarlah</surname><given-names>D.</given-names></name><name><surname>Carreira</surname><given-names>E.M.</given-names></name><etal/></person-group>
<article-title>Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction</article-title>
<source>Cell Rep.</source>
<year>2013</year>
<volume>5</volume>
<fpage>895</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2013.10.033</pub-id>
<pub-id pub-id-type="pmid">24268777</pub-id></element-citation></ref><ref id="B50-viruses-07-02759"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Cuconati</surname><given-names>A.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Block</surname><given-names>T.M.</given-names></name><name><surname>Guo</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Interferon induction of IFITM proteins promotes infection by human coronavirus oc43</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2014</year>
<volume>111</volume>
<fpage>6756</fpage>
<lpage>6761</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1320856111</pub-id>
<pub-id pub-id-type="pmid">24753610</pub-id></element-citation></ref></ref-list></back></article>